CAR T-cell therapy is a novel approach to cancer adoptive immunotherapy. The ongoing regulatory reforms, such as the breakthrough therapy designation (BTD) and priority review pathway, have…
The wet age-related macular degeneration (AMD) market in the United States is replete with intravitreal (IVT) therapies—including Regeneron’s Eylea, Roche / Genentech’s Lucentis and Vabysmo,…
China’s biosimilar market has evolved rapidly over the past four years since the approval of Henlius Biotech’s HLX01—a biosimilar of Roche’s MabThera (rituximab)—in February 2019. As of 2022…
Multiple myeloma is an incurable hematological malignancy with a 100% mortality rate that affects a sizeable Chinese population every year. With the introduction of proteasome inhibitors and…
Sickle cell disease (SCD) is a rare genetic blood disorder characterized by polymerization of hemoglobin (Hb) in red blood cells that distorts them into a sickle shape. This sickling leads to…
Immune checkpoint inhibitors have had a transformative impact in many oncology settings since their entry into the marketplace a little over a decade ago. Their use continues to advance into…
2023 marks a pivotal year for the autoimmune space as numerous releases of biosimilar adalimumab challenge the market dominance of AbbVie’s Humira, one of the best-selling brands in the United…
Antibody-drug conjugates have proven to be a versatile and effective tool in treating a wide range of tumor types, establishing the drug class as a valuable weapon against cancer. The approval of…
Scleroderma, also known as systemic sclerosis (SSc), is a rare, progressive, and debilitating autoimmune disorder characterized by skin fibrosis, systemic inflammation, and vasculopathy that…
Bipolar disorder (BPD) is a chronic illness characterized by recurrent episodes of aberrant mood; patients may exhibit manic, depressive, or mixed symptoms between periods of stable mood. Treatment…